⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

January 1, 2026EJC Skin CancerOpen Access

Radiotherapy Outcomes in Distal Limb Skin Cancers Treated at a Large District General Hospital

E. Zahra S. Ellis

View Full Paper

Ask AI

Bookmark

Share

Implication

Post-hoc analysis examines vismodegib efficacy in skin cancers with PPI use affecting safety outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zahra et al. (2026) studied this question.

synapsesocial.com/papers/69e9b62685696592c86eaf17 https://doi.org/10.1016/j.ejcskn.2026.101052

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Proton pump inhibitor use and overall survival in patients with gastric adenocarcinoma treated with first-line immunotherapy: A real-world pharmacoepidemiologic study.Retrospective Study · 2026
2Association of concomitant proton pump inhibitor use with worse survival outcomes in patients with advanced gastric cancer receiving ramucirumab.2025 · 1 citations
3Proton Pump Inhibitor Use and Survival Outcomes in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Immunotherapy: A Real-World StudyCohort Study · 2026
4Vismodegib treatment in locally advanced basal cell carcinoma limited to the facial region: a single-center experience2025
5A39-12 Proton Pump Inhibitor Use and Impact on Mortality and Clinical Outcomes in Idiopathic Pulmonary Fibrosis: A Propensity-Matched Cohort StudyCohort Study · 2026